Primary pleural epithelioid angiosarcoma treated successfully with anti-PD-1 therapy: A rare case report.

Abstract

RATIONALE:

Primary pleural angiosarcoma (PPA) is an extremely rare malignancy for which there is no consensus on treatment. The clinical course of PPA is usually quickly fatal, regardless of the treatment used.

PATIENT CONCERNS:

We describe the rare case of a 52-year-old man who presented initially with hemoptysis and received emergency surgery for the primary.

DIAGNOSES:

He received a confirmed diagnosis of primary pleural angiosarcoma (PPA) by postoperative pathology and was subsequently treated with radiotherapy and chemotherapy, but had failed and was intolerant to chemotherapy.

INTERVENTIONS:

The patient had 5% tumor PD-L1 positivity with 22C3 pharmDx and received pembrolizumab (200 mg every 21 days) for 13 cycles.

OUTCOMES:

The disease remained well controlled according to the RECIST 1.1. criteria. He is currently under observation and waiting to start the next cycle of immunotherapy.

LESSON:

Our case report suggests that the use of anti-PD-1 therapy does show efficacy in the treatment of PPA and may provide a viable treatment option for patients.

• Authors: Xia Wang, Jianping Wei, Zhimin Zeng, Jing Cai, Zhiqin Lu, Anwen Liu
• Journal: Medicine (Medicine (Baltimore)) Vol. 100 Issue 35 Pg. e27132 (Sep 03 2021) ISSN: 1536-5964 [Electronic] United States
• PMID: 34477160 (Publication Type: Case Reports, Journal Article)
• Copyright: Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

Chemical References

• Immune Checkpoint Inhibitors

Topics

• Humans
• Immune Checkpoint Inhibitors (therapeutic use)
• Male
• Middle Aged
• Pleura (pathology)
• Pleural Neoplasms (diagnostic imaging, drug therapy, pathology)
• Sarcoma (diagnostic imaging, drug therapy, pathology)
• Tomography, X-Ray Computed